Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 20.
doi: 10.1111/ceo.70031. Online ahead of print.

The Burden of Treatment for Sporadic Unilateral Retinoblastoma in Australia

Olivia Rolfe  1 , James Elder  1   2 , John McKenzie  1 , Anu Mathew  1 , Michael Sullivan  3 , Martin Campbell  3 , Elhamy Bekhit  4 , John Vrazas  4   5 , Sandra Staffieri  1   6   7   8 , Roderick O'Day  1   7
Affiliations

The Burden of Treatment for Sporadic Unilateral Retinoblastoma in Australia

Olivia Rolfe et al. Clin Exp Ophthalmol. .

Abstract

Background: The objective of this study was to compare the burden of treatment of different primary treatment modalities for unilateral sporadic retinoblastoma.

Methods: Sixty individuals with unilateral sporadic retinoblastoma were treated at the Royal Children's Hospital Melbourne, Australia, between January 2000 and December 2022. All International Classification of Retinoblastoma (ICRB) staging groups were included for analysis. The total number of anaesthetics and the total number of other hospital visits were calculated. The data was stratified by primary treatment modality and time from diagnosis (less than 12 months vs. beyond 12 months). The minimum follow-up period was 12 months from diagnosis.

Results: Average age at presentation was 24.85 ± 16.47 months. Forty children (66.7%) presented with ICRB Group E disease, 15 (25%) with Group D, 4 (6.7%) with Group C and 1 (1.6%) with Group B Disease. Forty-six (76.7%) children underwent primary enucleation, 9 (15%) underwent primary intravenous chemotherapy (IVC) and 5 (8.3%) were treated with intra-arterial chemotherapy (IAC). In the first 12 months following diagnosis, all measures of treatment burden were higher in children who underwent chemotherapy (intravenous or intra-arterial) compared to enucleation, except the number of ophthalmology outpatient appointments. Beyond 12 months of diagnosis, all measures of treatment burden were higher in children who underwent chemotherapy compared to enucleation alone, except the total number of anaesthetics and the number of day admissions. There were no deaths.

Conclusion: Globe-conserving therapies, such as primary IVC and IAC, are associated with a significantly higher burden of treatment compared to primary enucleation in the management of unilateral sporadic retinoblastoma.

PubMed Disclaimer

References

    1. E. S. Wong, R. W. Choy, Y. Zhang, et al., “Global Retinoblastoma Survival and Globe Preservation: A Systematic Review and Meta‐Analysis of Associations With Socioeconomic and Health‐Care Factors,” Lancet Global Health 10, no. 3 (2022): e380–e389.
    1. P. T. Finger and A. S. Tomar, “Retinoblastoma Outcomes: A Global Perspective,” Lancet Global Health 10, no. 3 (2022): e307–e308.
    1. V. Raval, R. C. Bowen, H. Soto, and A. Singh, “Intravenous Chemotherapy for Retinoblastoma in the Era of Intravitreal Chemotherapy: A Systematic Review,” Ocular Oncology and Pathology 7, no. 2 (2021): 142–148.
    1. T. Liang, X. Zhang, J. Li, X. Hua, P. Zhao, and X. Ji, “Intra‐Arterial Chemotherapy as Primary Treatment for Advanced Unilateral Retinoblastoma in China,” Frontiers in Medicine 9 (2022): 855661.
    1. A. Janic, A. Vincent, J. Stinson, and H. Dimaras, “Values of Retinoblastoma Survivors and Parents Regarding Treatment Outcomes: A Qualitative Study,” JCO Oncology Practice 18, no. 6 (2022): e1000–e1015.

LinkOut - more resources